Orion Pharma Scandinavia
Magnus L. has a diverse background in sales, marketing, and consulting, with significant experience in the pharmaceutical and hospitality sectors. Currently serving as a Produktspecialist at Orion Pharma Skandinavien since December 2021, Magnus oversees Easyhaler and Ryaltris in Västsverige. Previous roles include a marketing consultant for Sanofi and Merial at Ashfield Nordic, where Allegra achieved record sales, and owner of Ermacon, providing consulting services in sales, marketing, and IT. Additional experience includes consulting in sales and administration at Art2Dent AB, serving as an accountant at Revision 4U AB, and managing various hospitality establishments. Magnus holds a Bachelor's degree in Marketing from Uppsala University.
This person is not in any teams
Orion Pharma Scandinavia
Orion was founded in 1917 by Finnish pharmacists and has since grown into one of the Nordics' leading pharmaceutical groups. We work in a Scandinavian organization where we give everyone space to be themselves and we are convinced that it is the employees' genuine commitment that creates success. We create well-being and contribute to increased health and quality of life in patients, as well as build new collaborations with the healthcare sector. Our focus is to provide innovative originator medicines, cost-saving generics and biosimilars, as well as personal care and skin care products. We work in several different therapeutic areas, such as asthma/COPD, allergic rhinitis, cardiology, intensive care, neurology, and gastroenterology. Orion works to create added value for society, healthcare, and patients. ________________________________________________________________________________ Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. ________________________________________________________________________________ We cannot discuss our products on LinkedIn. If you have questions about any of our medicines or want to report a suspected side effect, please go to www.orionpharma.se/med for more information. Read more at www.orionpharma.se